ReviewBreathe (Sheffield, England)2026
Mechanisms of
Review in Breathe (Sheffield, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objectives: To summarise current evidence on 1) Mtb pathophysiology and immunopathogenesis; 2) mechanisms by which major viral, bacterial, fungal, and parasitic co-infections alter TB progress; and 3) infectious complications associated with PTLD. Content: Mtb exploits innate immune evasion, altered macrophage activation, and granuloma remodelling in order to persist. Viral co-infections, particularly HIV, influenza, and severe acute respiratory syndrome coronavirus 2, impair T-helper 1 immunity, disrupt cytokine signalling, increase bacterial load, and drive progression to severe or disseminated TB. Bacterial pathogens ( Conclusions: TB pathogenesis is profoundly influenced by co-infections, and PTLD is an under-recognised driver of chronic respiratory morbidity. Integrated diagnostics, coordinated management of multimorbidity, and tailored strategies for PTLD are essential to reduce TB-related burden.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.